



December 10, 2003

To All U.S./Puerto Rico Direct Purchasing Wholesalers and Specialty Distributors:

Over the past three years, there has been a significant increase in reported cases of counterfeit prescription medications in the U.S./Puerto Rico marketplace. We are deeply concerned about this disturbing trend and the threat it poses to public health. All of us directly involved in the pharmaceutical supply chain – wholesalers, distributors, and healthcare providers – must work together to ensure patient safety by protecting the supply chain from the potential entry of counterfeit drugs.

As you may be aware, J•O•M Pharmaceutical Services Division of Ortho-McNeil Pharmaceutical, Inc. (J•O•M),* is implementing a brand security program that includes the application of state-of-the-art anti-counterfeiting technologies to the packaging of our major products. We will continue to expand and modify these features over time.

In addition to applying anti-counterfeiting technologies, we are seeking to work collaboratively with our wholesaler and distributor partners to close the potential gaps in the supply chain that could allow for the entry of counterfeit products into the marketplace. The fact that counterfeit product exists in the supply chain confirms the challenges faced by wholesalers and distributors to distinguish between authentic and counterfeit products sourced through the secondary market.

To address the challenges presented by the secondary market – and to protect the patients we all serve – **all U.S. and Puerto Rico wholesalers and distributors are asked not to purchase, market, sell, or distribute any pharmaceutical or biopharmaceutical products of the companies asterisked below that have been directly obtained from any source other than J•O•M.** Sourcing products of the companies asterisked below from the secondary market will result in the loss of your status as a participating J•O•M wholesaler or distributor, and shipments of product by any J•O•M company to your business will cease.

To protect the integrity of our products and the safety of the patients who use them, we reserve the right to enforce this agreement by auditing, as necessary, your relevant documentation and records. Further, in the spirit of open communication, we will be alerting the marketplace to the new J•O•M distribution policy, and we will post a list of participating U.S./Puerto Rico J•O•M wholesalers and distributors to our website, www.jomdistribution.com, beginning January 26, 2004.

We know that you share our concerns regarding patient safety given the discovery of counterfeit product. Taking this step together will send a strong message to the marketplace that we will not tolerate activities that in any way compromise the health and well being of the patients that we serve.

Accepted and Agreed to:

Signed (by authorized officer) _____ **Date** ___/___/___

Printed Name _____ **Title** _____

Please return the original, signed copy of this letter via UPS by January 19, 2004, to Joseph T. Anstatt in the enclosed pre-paid envelope. A pre-printed label is included for your convenience.

Failure to comply with this requirement will result in the revocation of your status as a participating J•O•M wholesaler/specialty distributor, and shipment of product will cease on or before March 5, 2004. Should you have any questions, please call (800) 523-6225.

Thank you for your understanding and for your continued cooperation.

Sincerely,

A handwritten signature in black ink, appearing to read "J T Anstatt". The signature is fluid and cursive, with the first letters of the first and last names being capitalized and prominent.

Joseph T. Anstatt
Vice President of Planning and Distribution
Pharmaceutical Sourcing Group Americas

*Centocor, Inc., Janssen Pharmaceutica Inc., J•O•M Pharmaceutical Services Division of Ortho-McNeil Pharmaceutical, Inc., LifeScan, Inc., McNeil Consumer & Specialty Pharmaceuticals Division of McNEIL-PPC, Inc., Ortho Biotech Products, L.P., Ortho-McNeil Pharmaceutical, Inc., Ortho Oncology and Specialty Therapeutics Company division of Ortho Biotech Inc., and Scios Inc.